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Background: Tumor-associated macrophages (TAM) play an important role in tumor microenvironment.
Particularly, M2 macrophages contribute to tumor progression, depending on the expression of NF-κB.
Tumor-derived exosomes can modulate tumor microenvironment by transferring miRNAs to immune cells.
Epigallocatechin gallate (EGCG) has well known anti-tumor effects; however, no data are available on the influence
of EGCG on communication with cancer cells and TAM.
Methods: Murine breast cancer cell lines, 4T1, was used for in vivo and ex vivo studies. Exosome was extracted
from EGCG-treated 4T1 cells, and the change of miRNAs was screened using microarray. Tumor cells or TAM
isolated from murine tumor graft were incubated with exosomes derived from EGCG-treated and/or miR-16
inhibitor-transfected 4T1 cells. Chemokines for monocytes (CSF-1 and CCL-2), cytokines both with high (IL-6 and
TGF-β) and low (TNF-α) expression in M2 macrophages, and molecules in NF-κB pathway (IKKα and Iκ-B) were
evaluated by RT-qPCR or western blot.
Results: EGCG suppressed tumor growth in murine breast cancer model, which was associated with decreased
TAM and M2 macrophage infiltration. Expression of chemokine for monocytes (CSF-1 and CCL-2) were low in
tumor cells from EGCG-treated mice, and cytokines of TAM was skewed from M2- into M1-like phenotype by EGCG
as evidenced by decreased IL-6 and TGF-β and increased TNF-α. Ex vivo incubation of isolated tumor cells with
EGCG inhibited the CSF-1 and CCL-2 expression. Ex vivo incubation of TAM with exosomes from EGCG-treated 4T1
cells led to IKKα suppression and concomitant I-κB accumulation; increase of IL-6 and TGF-β; and, decrease of
TNF-α. EGCG up-regulated miR-16 in 4T1 cells and in the exosomes. Treatment of tumor cells or TAM with
exosomes derived from EGCG-treated and miR-16-knock-downed 4T1 cells restored the above effects on
chemokines, cytokines, and NF-κB pathway elicited by EGCG-treated exosomes.
Conclusions: Our data demonstrate that EGCG up-regulates miR-16 in tumor cells, which can be transferred to
TAM via exosomes and inhibits TAM infiltration and M2 polarization. We suggest a novel mechanism by which
EGCG exerts anti-tumor activity via regulation of TAM in tumor microenvironment.
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Worldwide, breast cancer is the most frequently diag-
nosed life-threatening cancer and the most important
cause of cancer-related deaths in women [1]. Population-
based investigations have suggested dietary factors which
affect the risk of breast cancer [2,3]. Epidemiological stud-
ies of Asian and Chinese women have reported an inverse
association between the consumption of green tea and the
risk of breast cancer. Of the polyphenols present in green
tea, epigallocatechin-3-gallate (EGCG) has been identified
as having inhibitory effects on tumorigenesis in studies
using in vitro and in vivo models of carcinogenesis [4-7].
Anti-tumorigenic activities of EGCG include inhibition of
cell proliferation, induction of apoptosis and cell cycle
arrest, inhibition of invasion and metastasis, and suppres-
sion of angiogenesis [8-13].
Exosomes are circular fragments of membrane released
from the endosomal compartment, and are shed from the
surface membranes of most cell types [14,15]. An increa-
sing body of evidence indicates that exosomes play a
pivotal role in cell-to-cell communication [16], and in par-
ticular, tumor cells are found to release large quantities of
exosomes [17-19]. The amount of circulating exosomes is
greater in the serum or plasma of patients with cancer
and predict a poor prognosis [17]. Release of exosomes
may protect tumor cells from apoptosis by selective
extrusion of apoptosis-inducing proteins. Additionally,
exosomes may help tumor cells escape the immune
surveillance [18] and carry out pro-angiogenic signals that
increase tumor vascularization [20]. In addition, exosomes
may transfer genetic information, such as microRNAs
(miRNAs) from tumor cells to neighboring cells [21].
Macrophages populate the microenvironment of most
tumors. In certain cases, these cells can represent more
than half of the tumor mass and play an important role
in tumor immunity, which is particularly true for breast
cancer [22]. Clinical studies have sought to correlate
macrophage density and cancer prognosis. A meta-
analysis have shown that, in 80% of the cases, increased
macrophage density was associated with poor prognosis,
and that, in the remaining 20%, there was a split bet-
ween null prognostic value and good prognostic value
[23]. Studies of this nature have been performed most
extensively for breast cancer, and multiple independent
investigations have found increased quantities of tumor-
associated macrophages (TAMs) to be associated with
poor prognosis [24]. In addition to the extent of macro-
phage infiltration, the phenotype of TAMs has been
shown to affect tumor progression [25]. Within the
tumor microenvironment, several stimuli are known to
influence the TAM phenotype. Macrophages can be in-
duced to either tumor-suppressive immunological type
(referred to as M1) or tumor-promoting inflammatory/
immune-suppressive population (M2 macrophages)[26,27]. Tumor cells produce colony-stimulating factor-
1 (CSF-1) and Chemokine (C-C motif ) ligand 2 (CCL2),
which are two major attractants and growth factors for
TAM. The concept that TAM are mainly M2 activated,
or even M2 ‘polarized’, has been around for almost a
decade, and is corroborated by the pattern of TAM
marker expression. High production of IL-10 and low
production of IL-12 is seen as a hallmark of all non-M1
macrophages, and is also applicable to most TAM popu-
lations in different cancer types. Accordingly, high fre-
quency of infiltrating TAM is associated with a poor
prognosis for many types of tumors. This pathological
association to clinical progression has reemerged in the
post-genomic era: genes associated to macrophage in-
filtration are the same molecular signatures that herald
poor prognosis in lymphomas and breast carcinoma
patients [28].
We hypothesized that EGCG might regulate the ex-
pression of tumor-derived exosomal miRNAs and affect
the tumor microenvironment and TAMs. The aim of
this study was to investigate the effect that EGCG has
on tumor-derived exosomal miRNAs and TAM.
Methods
Cell lines and reagents
The mouse mammary tumor cell line, 4T1, were main-
tained as monolayer cultures in Dulbecco’s Modified Eagle
Medium (DMEM), supplemented with 10% fetal bovine
serum (FBS), 100 units/ml penicillin, and 100 μg/ml
streptomycin (Gibco, Grand Island, NY, USA) in a hu-
midified 5% CO2/95% air atmosphere at 37°C. The murine
RAW264.7 macrophage cell line were grown in RPMI
1640 containing 10% fetal bovine serum 100 units/ml
penicillin, and 100 μg/ml streptomycin (Gibco, Grand
Island, NY, USA) in a humidified 5% CO2/95% air at-
mosphere at 37°C. Epigallocatechin gallate (EGCG) and
lipopolysaccharides (LPS) were purchased from Sigma
(St. Louis, MO, USA).
Transfection
The mouse mammary tumor cell line, 4T1 or macro-
phages cell line, RAW264.7 were plated on six-well plates
(2 × 105 cells per well) and were allowed to adhere for
24 hours. These cells were transfected with either
scramble miRNA inhibitor or miR-16 inhibitor using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Trans-
fected cells were then cultured for 6 hours, and culture
media were replaced with fresh media supplemented with
10% FBS. The cells were harvested at 24–48 hours after
transfection. The scramble miRNA inhibitor or miR-16 in-
hibitor (100 nM) were obtained from Shanghai Gene-
Pharma Co (Shanghai, China). The scramble miRNA
mimics or miR-16 mimics (100 nM) were obtained from
Genolution (Seoul, Korea).
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The 4T1 mouse mammary tumor cells (or TAM cells)
were centrifuged overnight at 100,000 g to isolate bovine-
derived exosomes which are present in the DMEM. The
exosomes from 4T1 cells were isolated from the re-
maining supernatants using ExoQuick (System Bioscience,
Mountain View, CA, USA) according to the manufac-
turer’s protocol. The pellets were washed in large volumes
of PBS and resuspended in 80 μl PBS. Proteins in pellets
and lysates were quantified by Micro-BCA (Thermo
Scientific) in the presence of 2% SDS. Purity of isolated
exosome was assured using electron microscopy by
exosomal size or immunobloting for CD63, tsg101, and
calnexin.
Quantification of miR-16 by RT-qPCR
The 4T1 mammary tumor cells were grown in 6 cm
Petri dishes to 70% confluence then were treated for 24
hr with 100 μM EGCG. Total RNA was extracted from
these cells using Trizol reagent (Invitrogen). The RNA
quality, yield, and size of extracted RNA were analyzed
using capillary electrophoresis (Agilent 2100 Bioanalyzer,
Agilent Technologies, Foster City, CA, USA). RT-qPCR
analysis for miRNAs was carried out with Mir-X™
miRNA First-Strand Synthesis Kit (Clontech, CA, USA)
and SYBR Green Real time PCR Master Mix (TaKaRa,
Otsu, Japan) according to the respective manufacturer’s
instruction. The house-keeping (HK) gene U6 was used
as a control for standardization of the initial miRNA
content of a sample. Relative changes of gene expression
were calculated by the following formula, and the data
was represented as fold up-regulation/down-regulation,
fold change = 2-ΔΔCt, where ΔΔCt = (Ct of gene of inte-
rest, treated -Ct of HK gene, treated)-(Ct of gene of
interest, control-Ct of HK gene, control). The primers
used were as follows: for miR-16, forward 5′-TAGCA
GCACGTAAATATTGGCG-3′; for U6, forward 5′-TG
GCCCCTGCGCAAGGATG-3, and miR-16 and U6 re-
verse primer was included in Mir-X™ miRNA First-
Strand Synthesis Kit.
Prediction of miRNA targets
Web resources was used to predict miR-16 targets, in-
cluding a viewer for browsing potential target sites, con-
served with or without positional constraints, on aligned
UTRs, with periodic updates (http://www.microrna.org).
Quantitative real-time RT-PCR (RT-qPCR)
Total RNA was extracted using Trizol (Invitrogen). For
RT-qPCR analysis, 5 μg of RNA was reverse-transcribed
using RT-PCR kits (Promega, Madison, WI, USA). PCR
was performed using SYBR Green Real time PCR Master
Mix (TaKaRa, Otsu, Japan). Relative changes of gene
expression were calculated by the following formula:ΔΔCt = (Ct of gene of interest, treated -Ct of HK gene,
treated)-(Ct of gene of interest, control-Ct of HK gene,
control); where, Ct was the threshold cycle number, and
HK was the house keeping gene.
This data was represented as fold up-regulation/down-
regulation, fold change = 2-ΔΔCt. The primer sequences
were used as follows: for TGF-β, forward sequence
5′- CACCGGAGAGCCCTGGATA-3′ reverse sequence




A-3′ reverse sequence 5′-GGTGAGGAGCACGTAGT
CGG-3′; CSF-1 forward sequence 5′-CGACATGGCT
GGGCTCCC-3′ reverse sequence 5′- CGCATGGTC
TCATCTATTAT-3′; CCL-2 forward sequence 5′-GT
TGGCTCAGCCAGATGCA-3′ reverse sequence 5′-A
GCCTACTCATTGGGATCATCTTG-3′; IL-1β, for-
ward sequence 5′-AAGGAGAACCAAGCAACGACA
AAA-3′ reverse sequence 5′-TGGGGAACTCTGCAG
ACTCAAACT-3′.; GAPDH forward sequence 5′- GGG
CTGGCATTGCTCTCA-3′ reverse sequence 5′- TGC
TGTAGCCGTATTCATTGT-3′.
Western blotting
For western blot analyses, the cells were harvested after
24 hours of exosomes treatment and lysed with lysis
buffer (5 mM/L ethylenediamine tetra acetic acid; 300
mM/L NaCl; 0.1% NP-40; 0.5 mM/L NaF; 0.5 mM/L
Na3VO4; 0.5 mM/L phenylmethylsulfonyl fluoride; and
10 μg/ml each of aprotinin, pepstatin, and leupeptin;
Sigma, St Louis, MO). Following centrifugation at 15,000 g
for 30 minutes, the concentrations of supernatant pro-
teins were analyzed using the Bradford reagent (Bio-
Rad, Hercules, CA). For analysis of protein contents,
50 μg of total proteins was electrophoresed in 10%
SDS-PAGE gel, transferred to polyvinylidene difluoride
membranes (Millipore, Bedford, MA), and were incu-
bated with antibodies against IKKα(Abcam), I-κB (Santa
Cruz Biotechnology), IL-6 (Invitrogen : AMC0864),
TNF-α (Abcam : ab1793), TGF-β (Abcam : ab64715) or
actin (Sigma). Immunoblots were visualized using an en-
hanced chemiluminescence detection system (Amersham
Pharmacia Biotech, Uppsala, Sweden).
Tumor-associated macrophages isolation from tumor
tissue
For ex vivo assay, the 4T1 cells (1 × 105) were suspended
in 100 μl PBS and then injected subcutaneously into
either side of the posterior flank of six BALB/c mice to
induce tumor growth. When these cells have established
as tumors after 3-to-4 weeks, the resulting tumor mass
were harvested for isolation of TAMs. Each tumor tissue
was cut into 2 mm fragments, followed by collagenase
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NJ, USA) for 1 h at 37°C. The suspension was filtered
through a 70-μm stainless steel wire mesh to generate a
single-cell suspension. This resulting suspension was
centrifuged and washed twice with PBS (pH = 7.4).
CD11b myeloid cells were purified from tumor cell sus-
pension using the MACS method (Militenyi Biotec).
Briefly, the CD11b cells were incubated with beads
conjugated with anti-mouse CD11b and were positively
selected on LS columns. The purity of recovered cells
assessed by flow cytometry was greater than 95%. The
viability of isolated cells routinely exceeded 90%, as
determined by trypan blue exclusion assays. These
TAMs (5 × 105/ml) were stimulated with the exosomes
(50 μg/ml) from the part of the experiment describe
above.
In vivo study
For in vivo assay, the 4T1 cells (1 × 105) were suspended
in 100 μl PBS and then injected subcutaneously into
either side of the posterior flank of six BALB/c mice.
Tumor growth was examined daily, and the tumor vo-
lumes were calculated every week using the formula for
hemi-ellipsoids: V = length (cm) × width (cm) × height
(cm) × 0.5236. After 5 weeks, each mouse was sacrificed,
and the tumors were dissected and weighed. Animals
experiment for this research was designed and carried
out according to the standard guideline of Institutional
Animal Care and Use Committee (IACUC), and the study
design had been approved by Seoul National University
Institutional Animal Care and Use Committee (http://
iacuc.snu.ac.kr).
Immunohistochemistry
Tumor tissue was fixed in 4% buffered neutralized forma-
lin for 48 hours. After embedding in paraffin, 4 μm serial
sections were made and mounted on a slide. Phenotypic
characterization of macrophages was performed using
double immunohistochemical staining to enable evaluation
of tumor cells. Antigens were retrieved by boiling tissue
sections in citrate buffer (DakoCytomation, Glostrup,
Denmark) for 10 minutes. Anti-mouse macrophage CD68
mAb (ab31630; Abcam, Cambridge, UK) was used as a
marker for all macrophages, and anti-mouse CD163 mAb
(NBP1-95135; Novus, Missouri, USA) as a marker for
M2-type macrophages.
Statistical analysis
We employed GraphPad Prism software to conduct sta-
tistical analysis. Results are expressed as the mean ± s.e.
m. For p-value calculation, unpaired Student's t tests
(two tailed) were utilized for all comparisons. Null hy-
potheses of no difference were rejected if p-values were
less than 0.05.Results
EGCG suppresses tumor growth, macrophages infiltration,
and M2 polarization in in vivo murine breast cancer
model
To determine if the presence of EGCG has influenced
tumor growth, TAM infiltration and differentiation, we
established a murine tumor model by injecting murine
breast cancer cell lines, 4T1, subcutaneously into syn-
geneic mice. Mice were then treated with EGCG either
PBS as a control by intraperitoneal injection as described
in Figure 1A. At 30 days after tumor challenge, a signifi-
cant decrease of tumor volume and weight was observed
in the EGCG-treated group versus the control group
(p < 0.0005) (Figure 1A and 1B). Intra-tumoral infil-
trations of TMA and M2 macrophages as assessed by
immunohistochemical staining were lower in EGCG-
treated group than control (Figure 1C).
We next measured the levels of CSF-1 and CCL-2,
major chemokines involved in the monocyte recruitment
into tumor microenvironment [29], in tumor cells iso-
lated from mice by RT-qPCR. In line with the decreased
number of TAM in EGCG-treated mice, expressions of
both CSF-1 and CCL-2 were significantly decreased
upon EGCG treatment (Figure 1D). Differentiation of
TAM into pro-tumoral M2 macrophages is induced by a
set of cytokines including IL-6 and TGF-β, and M2
macrophages produce much lower levels of TNF-α,
compared to M1 macrophages. Therefore, we isolated
TAM from mice and evaluated the expression of these
cytokines by RT-qPCR. TAM from tumors treated with
EGCG showed significant decrease of IL-6 and TGF-β
level, and higher expression of TNF-α compared with
those TAMs from control group (Figure 1E). NF-κB acti-
vation in macrophages within tumor microenvironment
has been known to differentiate TAM to pro-tumoral
and immunosuppressive M2 phenotype during the early
stage of tumor development [30]. Because IKKα has a
central role for mediating canonical NF-κB activation
pathway, we checked the level of IKKα in TAM from
mice by RT-qPCR and found that IKKα mRNA level was
significantly decreased in TAM of EGCG-treated group
compared with control group (Figure 1F).
Altogether these data suggested that EGCG treatment
suppresses in vivo TAM infiltration and inhibits pola-
rization of TAM into tumor-promoting M2 macro-
phages, which was involved by decreased production of
chemo-attractants, CSF-1 and CCL-2, from tumor cells,
and down-regulation of M2 macrophage-associated
cytokines, IL-6 and TGF-β and relative up-regulation of
M1 macrophage-associated cytokine, TNF-α, in TMA
from EGCG-treated tumor. Inhibition of NF-κB activity
of TAM by EGCG treatment might be implicated in
these processes. Importantly, our result suggested that
EGCG might exert anti-tumor activity by preventing
Figure 1 EGCG suppresses tumor growth, macrophages infiltration, and M2 polarization in in vivo murine breast cancer model.
(A) Balb/c mice were challenged with 1× 105 murine breast cancer cell lines, 4T1, by subcutaneous injection into the right flanks. EGCG
(10 mg/kg) or PBS (as a negative control) was administrated intraperitoneally (i.p.) on days 7, 9, and 11. Tumour sizes were measured every week
until day 30 post tumour challenge. (B) Mice were sacrificed and the tumors were dissected and the weight was measured. (C) For evaluation of
tumor-associated macrophages and M2 macrophage infiltration, immunohistochemical staining for CD68 and CD163 was done using tumor
tissue. (D) Tumor cells were isolated and total RNA was extracted and then subjected to RT-qPCR to measure the levels of CSF-1, CCL-2, and
GAPDH. Histogram shows the relative expression of molecules compared to GAPDH as internal control. (E) Tumor-associated macrophages were
isolated, and total RNA from these cells were extracted and subjected to RT-qPCR to detect levels of M2high cytokines (IL-6 and TGF-β) and M2low
cytokine (TNF-α). Histogram shows the relative expression of molecules compared to GAPDH as internal control. (F) Tumor-associated
macrophages were isolated and total RNA from cells were extracted and then subjected to RT-qPCR to detect the level of IKKα and GAPDH
(internal control).
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microenvironment.
Exosomes derived from EGCG-treated tumor cells leads to
decrease of CSF-1 and CCL-2 expression in a paracrine
manner, and suppresses M2 polarization of TAM in
ex vivo study
Tumor cells release chemo-attractants to recruit and acti-
vate macrophages in a paracrine loop between tumors and
macrophages, and this release promotes breast cancer in-
vasion [31]. Exosomes could play an important role of
communication between tumor cells and macrophages. In
order to determine whether the effect of EGCG observed
in the in vivo mouse model could be mediated by tumor
exosome, we carried out the ex vivo experiments using the
exosomes extracted from 4T1 cell lines. As shown in
Figure 2A, treatment of tumor cells with EGCG resulted
in a significant decrease of both CSF-1 and CCL-2 ex-
pression. In addition, ex vivo incubation of TAM withexosomes from EGCG-treated 4T1 cells skewed polarized
these macrophages away from the tumor-promoting M2-
to a tumor-inhibiting M1-like phenotype, as evidenced by
down-regulated the expression of IL-6 and TGF-β, but
up-regulated TNF-α expression (Figure 2B). We con-
firmed the protein levels of IL-6, TGF-β, and TNF-β and
obtained results same as in RT-qPCR (Figure 2C). These
data indicated that exosomes derived from EGCG-treated
tumor cells suppress TAM infiltration and inhibit TAM
differentiation into M2 macrophages in murine breast
cancer model.
EGCG up-regulates cellular and exosomal miR-16 levels in
murine breast cancer cells, 4T1
To investigate the mechanism by which EGCG treat-
ment had led to decreased TAM infiltration and inhi-
bition of M2 polarization via exosomes, we focused on
the effect of EGCG on the regulation of tumor exosomal
miRNA. We hypothesized that EGCG might change the
Figure 2 Exosomes-derived from EGCG-treated tumor cells down-regulate chemo-attractants in tumor cells, and suppress M2
polarization of tumor-associated macrophages in ex vivo model. (A) Tumor cells were isolated from established murine breast cancer using
4T1 cell line as in Figure 1, and were treated with EGCG (100 μM). After 24 hours of incubation, total RNA from cells were extracted and
subjected to RT-qPCR to detect the levels of CSF-1, CCL-2, and GAPDH. Histogram shows the relative expression of molecules compared to
GAPDH as internal control. (B) Tumor-associated macrophages were isolated from established murine breast cancer using 4T1 cell lines, and were
treated with exosomes (50 μg/ml) derived from EGCG-treated or untreated 4T1 cells. After 24 hours of incubation, total RNA from cells were
extracted and subjected to RT-qPCR to evaluate the levels of M2high cytokines (IL-6 and TGF-β) and M2low cytokine (TNF-α). Histogram shows the
relative expression of molecules compared to GAPDH as internal control. (C) Tumor-associated macrophages were isolated from established
murine breast cancer cell lines, and treated with exosomes (50 μg/ml) derived from EGCG-treated or untreated 4T1 cells. After 24 hours of
incubation, total lysates from cells were extracted and subjected to Western-blot to evaluate the protein levels.
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exosomal compartment, and that the exosomal miRNA
to TAM would influence on the recruitment and dif-
ferentiation of TAM. To address this issue, we first
screened the miRNAs whose expressions are modulated
in 4T1 cells by miRNA microarray analysis using both
total cellular miRNA and exosomal miRNA after treat-
ment with 100 μM of EGCG for 24 h. In brief, a set of
miRNAs including let-7, miR-16, miR-18b, miR-20a,miR-25, miR-92, miR-93, miR-221, and miR-320 were
up-regulated, and dozens of miRNAs including miR-10a,
miR-18a, miR-19a, miR-26b, miR-29b, miR-34b, miR-98,
miR-129, miR-181d were down-regulated in both total
cellular and exosomal fraction by EGCG treatment (data
not shown). Of these, miRNAs up-regulated by EGCG
were suitable for further in vitro study because it is more
likely that over-expressed miRNA could be stored within
exosome and then transferred to TAM. Specifically, the
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treatment and has been known to be associated with im-
mune cell function.
To validate the microarray data, 4T1 cells were incu-
bated with EGCG, and the total RNA was extracted
from cells and secretory exosomes. This was then ana-
lyzed by RT-qPCR. Significant up-regulation of miR-16
in both EGCG-treated cells and exosomes was observed
with a 1.45 and 2.54 folds change compared with the
levels of controls (p < 0.05 and p < 0.005, respectively)
(Figure 3).
Up-regulation of exosomal miR-16 by EGCG treatment
down-regulates IKKα and subsequently induces IκB
accumulation in TAM, and inhibits M2 polarization
MiR-15a and miR-16 have been known to act as a nega-
tive regulator of NF-κB activity by regulating IKKα ex-
pression, which contributes to the ability of miR-15 and
niR-16 as a tumor suppressor. NF-κB activation is also
important for monocyte differentiation into macrophage
and TAM. In fact, a study has reported that during
monocyte-macrophage differentiation, expressions of
miR-15a and miR-16 were decreased with higher expres-
sion of the IKKα [30].
As already known, we identified the possible target
sequence in the 3′-UTR of IKKα for miR-16. Therefore,
we tested whether exosomes derived from EGCG-Figure 3 EGCG increases cellular and exosomal miR-16 expression in
without EGCG (100 μM) for 48 hours. Then, total RNA from cells or secretor
miR-16 level. Histogram shows the relative expression of miR-16 comparedtreated 4T1 cells could suppress IKKα expression and, if
so, whether that process occurs through exosomal
miR-16. As shown in Figure 4A, the treatment of TAM
with exosomes from EGCG-treated 4T1 cells has
resulted in decreased IKKα protein expression and con-
comitant accumulation of the I-κB in TAM. Moreover,
when TAM was incubated with exosomes from EGCG-
treated and miR-16 inhibitor-transfected 4T1 cells, IKKα
levels had recovered to the that of the control (4T1
exosome treated TAM) (Figure 4B). MiR-16 expression
was not elevated in exosomes from EGCG-treated and
miR-16 inhibitor-transfected 4T1 cells (data not shown),
unlike exosomes from EGCG-treated 4T1 cells where
miR-16 was up-regulated by EGCG (Figure 3).
To test whether exosome from EGCG-treated 4T1
cells could inhibit M2 polarization of TAM through
exosomal miR-16, we treated TAM with exosomes either
from EGCG-treated 4T1 cells or from from EGCG-
treated and miR-16 inhibitor-transfected 4T1 cells, and
measured the level of cytokines including IL-6, TGF-β,
and TNF-α. Consistent with the in vivo data (Figure 1E),
incubation of TAM with exosomes from EGCG-treated
4T1 cells had led to the suppression of M2-associated
cytokines, IL-6 and TGF-β, and elevation of the M1-
related cytokine, TNF-α (Figure 4C). More importantly,
this alteration of cytokines was restored when TAM was
incubated with exosomes from EGCG-treated and miR-murine breast cancer cell line, 4T1. 4T1 cells were treated with and
y exosomes was extracted and subjected to RT-qPCR to assess the
to U6 as an internal control.
Figure 4 Exosomes derived from EGCG-treated tumor cells suppresses NF-κB pathway and inhibits M2 polarization of tumor-
associated macrophages, which is dependent on up-regulated miR-16 in EGCG-treated tumor exosomes. (A) Tumor-associated
macrophages were isolated from established murine breast cancer 4T1 cell lines, and treated with exosomes extracted from EGCG (100 μM)-
treated and untreated 4T1 cells for 24 hours. Whole cell lysates were prepared and submitted to Western blot using anti-IKKα, anti-I-κB or
anti-actin antibodies. (B) 4T1 cells were incubated with EGCG (100 μM) and simultaneously (24 hours) transfected with scramble or miR-16
inhibitor for 24 hours. Exosomes were then extracted from each tumor cells. Tumor-associated macrophages isolated from established murine
breast cancer were treated with each exosome as indicated at the concentration of 50 μg/ml for 24 hours, and whole cell lysates were prepared
and submitted to Western blot using anti-IKKα or anti-actin antibodies. The numbers in Figure 4A and 4B report the quantification of bands by
imaging analysis with KODAK Molecular Imaging Software (MI). (C) 4T1 cells were incubated with EGCG (100 μM) and were simultaneously
(24 hours) transfected with scramble or miR-16 inhibitor for 24 hours. Exosomes were then extracted from each tumor cells. Tumor-associated
macrophages isolated from established murine breast cancer were treated with each exosome at the concentration 50 mg/ml for 24 hours, and
total cellular RNA was extracted and submitted to RT-qPCR analysis for M2high cytokines (IL-6 and TGF-β) and M2low cytokine (TNF-α). Histogram
shows the relative expression of molecules compared to GAPDH as internal control. (D) Tumor cells were isolated and total RNA from cells were
extracted and subjected to RT-qPCR to measure the miR-16 level. Histogram shows the relative expression of miR-16 compared to U6 as an
internal control.
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fied that the levels of miR-16 are reduced by transfection
of miR-16 inhibitor (Additional file 1). Finally, weobserved a 1.68-fold increase of miR-16 expression in
tumor cells from mice treated with EGCG compared to
control (Figure 4D). To investigate modulation of
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RAW264.7, cells was transfected with scramble or miR-16
mimics and stimulated with 5 μg/ml LPS. We found that
miR-16 mimics significantly suppressed LPS-induced
IL-1β and IL-6 production in these RAW264.7 cells
(Additional file 2).
Together, the results suggest that EGCG treatment
leads to up-regulation of miR-16, which might be trans-
ferred by exosomes to TAMs, and contributes to the
suppression of NF-κB activity by down-regulating IKKα
and subsequently accumulating Iκ-B, and inhibition of
TAM infiltration and M2 polarization. These molecular
pathways might represent a new mechanism by which
EGCG exerts anti-tumor effect through manipulating
TAM and tumor microenvironment, as illustrated in
Figure 5.
Discussion
Exosomes are vesicles with a diameter of 50–100 nm se-
creted from intracellular endosomes. These vesicles are
unrelated to the RNA exosome, which is an RNA-
processing intercellular complex. Membrane vesicles,
which are also referred to as microvesicles or micropar-
ticles, have a diameter of 100–1,000 nm and are pre-
sumed to be formed by budding or shedding from
plasma membrane [32]. Studies of the functional contri-
butions of these vesicles to intercellular communication
have focused on understanding the role of their mem-
branous and cytoplasmic protein content. A role in the
modulation of immune function has also emerged be-
cause the cellular microenvironment is a critical deter-
minant of tumor progression and development [33].
There is much interest in intercellular communication
between tumor cells and immune cells in the tumor
microenvironment. Cells use a variety of approaches toFigure 5 Proposed mechanisms of EGCG to inhibit infiltration of tum
tumor microenvironment.communicate with each other, such as direct membrane-
to-membrane contact or by the release of soluble media-
tors. Among these various means of information transfer,
exosomes represent a unique way to mediate cell-to-cell
communication [34-38]. Exosomes contain membrane
proteins similar to those of the donor cell and contain
protein and RNA derived from the donor cell cytoplasm
[39]. These vesicles can be taken up and transfer the
intravesicular content into the host intracellular environ-
ment, which subsequently modulates cellular activities of
the recipient cells. Thus, exosomes provides cells with the
ability to signal and transfer the intracellular molecular
content within the local microenvironment as well as to
distant locations [40].
Recently, it has been found that exosome is an impor-
tant physiologic vehicle carrying and delivering miRNA.
When introduced into a new cytoplasmic space, mature
miRNAs associate with the RNA-induced silencing
complex to effect gene expression [41]. The selective en-
richment of these miRNAs in cellular exosomes, the
consistency in expression between different isolations,
and the cell-type specificity indicate the presence of a
mechanism for their active elaboration within these
particles. This may arise from selective transport into a
membrane-bound exosome or from sequestration of
proteins that are selectively enriched within the exo-
some. Alternatively, the possibility exists that these
miRNAs are rapidly degraded within the cytoplasm, but
are protected from degradation when they are seques-
tered in vesicles before their elaboration from cells as
cellular exosomes. Because the tumor cells studied vary
in cellular behavior, it is not unexpected that some dif-
ferences in miRNA content were noted between various
cell types [42]. These observations regarding cell-type
specificity of miRNA content are similar to those madeor-associated macrophages and M2 polarization in
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emphasize the need to study and interpret data on indi-
vidual cell-type basis.
In the present study, a selective set of miRNA was
present within EGCG-treated exosomes which was mark-
edly different from that from untreated breast cancer cells.
Among the miRNAs by modulated by EGCG, we focused
on miR-16 because it had been identified as one of the
down-regulated miRNAs in murine and human breast
cancer cells. Additionally, targets of miR-16 include many
genes related to the control of cell-cycle progression, such
as cyclin D1, cyclin E, and the anti-apoptotic protein,
Bcl-2 [43-45]. The restoration of miR-16 in prostate can-
cer cells results in growth arrest, apoptosis and in marked
regression of prostate tumor xenografts [45]. A thera-
peutic strategy is underway that involves the delivery of
synthetic miR-16 into advanced prostate tumors [46].
Overexpression of miR-16 was shown to suppress the self-
renewal and growth of mouse breast tumor stem cells and
to sensitize MCF-7 human breast cancer cells to the che-
motherapeutic drug doxorubicin [47]. In addition to the
role of tumor suppressor, miR-16 plays a role in macro-
phages. For example, IKKα mRNA is a target for miR-15
and miR-16. During monocyte-to-macrophage differen-
tiation, a substantial decrease in these miRNAs allows for
a considerable increase in IKKα protein and for the sub-
sequent activation of NF-κB pathway [29]. In this study,
we have revealed for the first time that EGCG modulates
the miRNA profile within tumor exosomes and upre-
gulates miR-16, which was responsible for EGCG-treated
exosome down-regulating IKKα and inhibiting M2 pola-
rization of TAM. Considering that miR-16 can function as
a tumor suppressor, it is possible that up-regulated
exosomal miR-16 might also have had an effect on the
survival and proliferation of tumor cells in our in vivo
experiment.
Macrophage infiltration was decreased by EGCG treat-
ment in the mouse tumor model. To claim that these re-
sults are originated from the EGCG-mediated inhibition
of macrophage recruitment and M2 polarization rather
than the effect of EGCG on macrophage proliferation,
we treated TAM isolated from mouse with exosome
from EGCG-treated 4T1 cell lines. In these ex vivo ex-
periments, we did not observe any decrease in macro-
phage numbers. However, the mobility of macrophage
(data not shown) and the change of phenotype toward
non-M2-like macrophages were found to be decreased.
It has been known that NF-κB activation is important
for macrophage-to-M2 macrophage differentiation and
contributes to tumor progression. Therefore NF-κB in
TAM is considered as a novel therapeutic target for
cancer control. However, several studies have recently
suggested that NF-κB in TAM could have a more com-
plicated and multifaceted role during tumor initiationand progression [48]. For example, in an established
murine fibrosarcoma model, the maintenance of M2-
phenotype was associated with defective NF-κB activa-
tion. This paradoxical role of NF-κB in TAM requires
further investigation, and should be addressed in a
tumor model-specific manner. The ex vivo experi-
ments, using macrophages from established murine
breast tumor instead of blood monocytes, would re-
flect the effect of EGCG on TAM during tumor pro-
gression rather than tumor initiation. However for the
in vivo experiment, EGCG was administrated at the
early period after tumor transplantation. We observed
the down-regulation of NF-κB pathway in terms of
IKKα and I-κB expression in TAM by EGCG or
EGCG-treated exosomes in vivo and ex vivo, which we
think would be the molecular mechanism underling
the EGCG-mediated hindrance of infiltration and dif-
ferentiation of macrophages into tumor-promoting M2
macrophages, although direct evidences are lacking.
EGCG has been reported to have anticancer bio-
logical activity as well. The main mechanism of this ac-
tivity involves the inhibition of cell proliferation and
induction of apoptosis [34,35]. EGCG can inhibit the
cellular proliferation in skin cancer, lung cancer, oral
cancer, gastric cancer, intestinal cancer, colon cancer,
hepatocellular carcinoma, pancreatic cancer, rectal
cancer, prostate cancer and breast cancer, suggesting
that EGCG could be utilized as a potential anti-cancer
drug [16,36,37]. However, regulation of exosomal
miRNAs by EGCG in tumor cells has not previously
been studied. We sought to evaluate the ability of
breast cancer cells to release vesicles capable of modu-
lating immune response and to investigate modulation
of these vesicles by treatment with EGCG. In the
present study, we showed that EGCG can modulate the
miRNA contained within exosomes and suppresses im-
mune response, and particularly tumor-associated
macrophages. The significance of the experiments in
this study is that the mechanism by which EGCG me-
diates communication between the tumor cells and im-
mune cells has been revealed for the first time.
Whether this scenario is applicable to other tumors re-
mains to be elucidated.
Conclusions
In this study, we demonstrated that EGCG can sup-
press tumor growth through the inhibition of TAM
infiltration and M2 polarization, using in vivo and
ex vivo murine breast cancer model. Moreover, we re-
vealed that EGCG modulates miRNAs, particularly up-
regulates miR-16, which is transferred to adjacent
tumor cells and TAM via tumor-derived exosomes and
which has an influence on macrophages in tumor
microenvironment.
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Additional file 1: 4T1 cells were incubated with EGCG (100 μM) and
simultaneously (24 hours) transfected with scramble or miR-16
inhibitor for 24 hours. Exosomes were then extracted from each tumor
cells, and total RNA from these cells were extracted and subjected to
RT-qPCR to measure the miR-16 level. Histogram shows the relative
expression of miR-16 compared to U6 as an internal control.
Additional file 2: RAW264.7 cells were stimulated with 5 μg/ml LPS
in the transfection scramble or miR-16 mimics, and total cellular
RNA was extracted and submitted to RT-qPCR analysis for IL-1β and
IL-6. Histogram shows the relative expression of molecules compared to
GAPDH as internal control.
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